Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I thought Manuel came from Madrid?
"Thanks for telling us all nothing bald, yet again."
======================================
So Volatility tell us, what have you got to bring to the table?
I reckon BoC has talked the most sense...there isn't enough information to make a call (at the moment).
PS I wasn't really interested in Parker & Manuel in the first place....apart from 'Nosey' Parker being a Thunderbirds character.
PPS Slightly interesting that Manuel 'lives' in Guildford (where FUM are headquartered).
"bald - or it could all be Mr Parker's own hard-earned £s"
=====================================================
Or he could have found a pot of Lepruchaun gold....just to keep the Fantasy island brigade & fairy dust crowd happy!!
Really where Mr Parker (founder of CBDerma Tech Ltd) gets his money from is pure speculation on our part...that doesn't really tell us anything.
The 'fact' that Mr Parker & Dr Manuel may be in contact with Mr Barder is interesting but again doesn't raelly tell us very much. Although one would suspect that they have some sort of endgame in mind (being 'successful' finance men). From what Mr Barder said on Proactive they have decided on the 'easiest' way to get to market via a cosmetic route. But like anything, developping & marketing a new product from scratch isn't likely to be cheap.
Dr David Manuel Linkedin profiles shows 'Guildford, UK'....which may make him a drinking buddy of Mr Barder or an acquaintance at least. So it makes sense that BeaglePartners are associated with CBDerma Tech Ltd and FUM in some way. What they hope to achieve is anyones guess. I suppose they could be developping IP to sell on or perhaps they really want to get a product to market ...some form of cosmetic initially.
theItalian, thanks for the Parker info. I looked at the BeaglePartner website....they (Manuel & Parker) could be the backers behind CBDerma TEch Ltd. I'm not sure what it adds to our knowledge knowing who they are. It doesn't really tell us their intentions, resourcesor ultimate goal. They may or may not think $1m is chickenfeed....but like all businessmen they will want to see some tangible return on their investment. Obviously they may be getting grants that cover some of their initial investment, so they might not have as much 'skin in the game' as we think.
he is the sole director and shareholder in cbderma.however he is also one of two partners in beagle partners llp.see my 15.09 post yesterday with link.i have tried posting a link yesterday to the linkedin page of the other partner ,david manuel,but it does not seem to work.if you can access it it's worth a read,wearing the appropriately coloured spectacles of course(not rose tinted).strangely i can no longer access it on my computer but i think that is a problem at my end.
"I'm pretty sure Mr Parker's put some money into CBD research for a good reason."
===================================
I might have missed it yesterday, but who is Mr Parker?....apart being a chauffeur of course!
BoC, I suspect you are wisely viewing CBD100 as the cherry on top of the cake. It may turn into something more substantial, but it may turn into nothing.
At the moment the risk to FUM seems minimal and the reward is unquantified....although it is a sexy thing to include in FUM's PR. Could all be hot air of course...like a lot of PR from AIM companies in general.
baldy - good to engage you in some useful debate today (most of your posts I ignore). For clarity, I'm not buying into the CBD thing until more information becomes available. There is loads of stuff kicking around about MED3000, meaning investors can at least try to form a balanced view on it. CBD - different story, I need more to decide whether it truly bolsters FUM's position and value in the future.
"....I'm sold (for now) on MED3000's potential but need something more credible on CBD100, otherwise it looks like an unnecessary distraction (which can be fatal for a small business). As long as they don't shift focus too much from the main event..."
=================================================
BoC, I see what you mean. You are concerned that CBD100 could distract resources away from MED3000 and delay it getting to market. Hopefully FUM management are aware of that danger. They can also sub-contract work to external contractors (such as Professor David Ralph)....but presumably at increased cost to themselves.
" looks like that number has been picked at random"
======================================================
BoC, I'm not sure what you mean. The $1m was the maximum amount allocated by CBDerma Tech Ltd for the work undertaken by FUM. Presumably they would be 'happy' for it to be less than $1m but not to exceed it.
I'm not sure we need to know where the money comes from....unless it is drug money!! (Russian money would be acceptable I expect). As long as the money keeps flowing to fund FUM's development then happy days. Worse case if FUM are asked to contribute towards future development in cash terms....this would have to be factored in for the fund raising.
To say it's going to cost $1m, not point to where it is coming from and also say it will be immaterial on cashflow is a bit amateur in my view. Like I said yesterday, I'm sold (for now) on MED3000's potential but need something more credible on CBD100, otherwise it looks like an unnecessary distraction (which can be fatal for a small business). As long as they don't shift focus too much from the main event I'm happy to wait for more information.
yes, but where is the $1m coming from? looks like that number has been picked at random
"Who’s Responsible for the Safety of Cosmetics?
FDA does not have the legal authority to approve cosmetic products and ingredients (other than color additives) before they go on the market. We also do not have a list of tests required for any particular cosmetic product or ingredient. However, a manufacturer or distributor of a cosmetic is legally responsible for ensuring that a marketed product is safe when consumers use it according to the directions in the labeling or in the customary or expected way. FDA can take action against the manufacturer of a cosmetic on the market if we have reliable information to show that a cosmetic does not meet the legal requirement for safety" [https://www.fda.gov/cosmetics/cosmetics-science-research/product-testing-cosmetics]
FUM & CBDerma Tech Ltd will need to undertake testing to ensure any cosmetic product is safe...especially in the USA where people like to litigate!!
"Initial development costs are expected to be in the region of US$ 1 million and will cover all development costs incurred by the Company during the next 15 months in order to develop and optimise a DermaSys®- cannabidiol formulation as well as establishing early ex-vivo proof of concept studies likely to include certain disease states most suited for local or regional (non-systemic) topical treatment such as pain relief. The Company does not expect this project's initial development to have any material impact on cashflow as Futura's financial share of the project will be delivered from its expertise and existing internal resources."
So the initial $1m is budgeted to last until approx the end of the year. This was intended for ex vivo testing. So any trial on real humans will presumably require some additional funding, possibly early next year.
"All Intellectual Property will be owned jointly by the Company and CBDerma Technology Limited."
It would be interesting to know what sort of deal they have with CBDerma Tech ltd - but that will be commercially sensitive information. FUM will have a contract with them to provide a certain level of development and presumably CBDerma have agreed to fund (or contribute a certain amount) to that development. We also don't really know who is calling the shots on where the commercialisation is headed. Typically FUM funds development and has full control of the roadmap - which has so far meant trials followed by regulatory submission. The feedback from Mr Barder suggests a change from this model.
We also don't know whether FUM will have full ownership of the IP (I presume they will) and how much money FUM will get in royalties from following the cosmetic skincare route to market. Lots of questions that we may never get the answer to....the only certainty will be increasing revenues at FUM.
Even cosmetic products need to be tested for safety, so some form of trial using real humans must be required...I expect passing quite high amounts of cannabidiol through the skin needs to be investigated for side effects and long term safety (rashes are an obvious concern).
ok fair enough BE.i did wonder but obviously took it the wrong way.good job I'm not really italian though (cosa nostra and all that).i don't imagine they are planning to start selling face cream etc.but if they do end up producing a more effective delivery system for manufacturers who wish to use it then i imagine it could be extremely lucrative.anyway we re a long way off that atm.other fish to fry first i hope.
theItalian, I didn't realise you don't have a sense of humour...I thought Italians liked a good joke, Mussolini & Berlosconi good examples. The hemp clothing range should have given it away...with Barders face embroidered on them.
No seriously, I don't think selling cosmetics is going to enhance FUM's credibility as a serious pharma company in the industry....but I suppose beggars cannot be choosers.
hardly a balanced or fair assessment of the situation or my comments on it.to be honest your post is,imo,nonsense.if they had announced they were abandoning all other activities it might have some relevance,but as they have not, it does not. just another possible line of exploration.previous respect all gone now I'm afraid. far too much bile and bias for my taste
So FUM is going to morph into some sort of gimmicky cosmetic company in pursuit of a quick buck...perhaps a sideline of hemp clotheswear with Mr Barder's visage on the front. I suppose they have to pay the bills somehow!!
i would suggest that anyone who has not yet done so should listen to barders video today on the cbd update.as always with these, watch them with a very liberal does of scepticism, as they are entirely self promotional, what is interesting about this one is that it gives an insight into the focus re CCBD, which is not made explicit in the RNS. it seems the initial focus is on the cosmeceutical market, under which products may not make medical claims, but equally do not have to undergo pharma trials to prove claims. think along the lines of a superior (or at least perceived by the consumer as such) skin cream, that sort of thing. certainly not wishing to overstate anything here and it may all come to nothing, but if successful, has the potential to be marketed much sooner than something which requires trials. still very very early days, but important i think that investors at least understand the targeted market etc.